Applied Genetic Technologies - AGTC Stock Forecast, Price & News

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, LLC; and Otonomy, Inc. Applied Genetic Technologies Corporation was incorporated in 1999 and is headquartered in Alachua, Florida.

Applied Genetic Technologies Stock Performance

Shares of NASDAQ:AGTC remained flat at $0.43 during mid-day trading on Thursday. The company had a trading volume of 1,085,556 shares, compared to its average volume of 793,766. The firm has a market capitalization of $21.73 million, a price-to-earnings ratio of -0.29 and a beta of 1.32. The company has a debt-to-equity ratio of 0.24, a quick ratio of 2.73 and a current ratio of 2.73. Applied Genetic Technologies has a 1-year low of $0.35 and a 1-year high of $3.73. The stock's 50-day moving average price is $0.63 and its 200 day moving average price is $1.13.

Applied Genetic Technologies (NASDAQ:AGTC - Get Rating) last announced its earnings results on Monday, May 16th. The biotechnology company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.09. Equities research analysts expect that Applied Genetic Technologies will post -1.49 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on AGTC shares. StockNews.com started coverage on Applied Genetic Technologies in a research report on Sunday. They set a "sell" rating on the stock. Stifel Nicolaus restated a "buy" rating and issued a $10.00 price objective on shares of Applied Genetic Technologies in a report on Thursday, April 14th. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Applied Genetic Technologies in a report on Tuesday, May 17th. One analyst has rated the stock with a sell rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $15.00.